

Radioembolization of HCC in 2017

A/Professor Lourens Bester.

University of Notre Dame, Australia.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. Radioembolization has shown a promising efficacy in terms of disease control and is associated with a good safety profile. Accurate diagnosis and staging using BCLC allows practitioners to apply the most appropriate treatment of which SIRT is one. The workup and implantation procedure will be discussed taking into consideration that there are two types of microspheres being used to treat HCC. The recently prospective studies SARAH and SIRveNIB will be eluded to and their impact on management will be highlighted.